0000891293-18-000087.txt : 20180920
0000891293-18-000087.hdr.sgml : 20180920
20180920170344
ACCESSION NUMBER: 0000891293-18-000087
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180918
FILED AS OF DATE: 20180920
DATE AS OF CHANGE: 20180920
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: KIRSKE DAVID
CENTRAL INDEX KEY: 0001276750
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-28386
FILM NUMBER: 181079972
MAIL ADDRESS:
STREET 1: C/O CTI BIOPHARMA CORP.
STREET 2: 3101 WESTERN AVE., SUITE 600
CITY: SEATTLE
STATE: WA
ZIP: 98121
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: CTI BIOPHARMA CORP
CENTRAL INDEX KEY: 0000891293
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 911533912
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 3101 WESTERN AVENUE
STREET 2: SUITE 800
CITY: SEATTLE
STATE: WA
ZIP: 98121
BUSINESS PHONE: 2062827100
MAIL ADDRESS:
STREET 1: 3101 WESTERN AVENUE
STREET 2: SUITE 800
CITY: SEATTLE
STATE: WA
ZIP: 98121
FORMER COMPANY:
FORMER CONFORMED NAME: CELL THERAPEUTICS INC
DATE OF NAME CHANGE: 19960321
4
1
primary_doc.xml
PRIMARY DOCUMENT
X0306
4
2018-09-18
0
0000891293
CTI BIOPHARMA CORP
ctic
0001276750
KIRSKE DAVID
3101 WESTERN AVE., SUITE 800
SEATTLE
WA
98121
0
1
0
0
EVP, Chief Financial Officer
Non-Qualified Stock Option (right to buy)
1.88
2018-09-18
4
A
0
125000
0
A
2028-09-18
Common Stock
125000
125000
D
The stock options will fully vest upon the Compensation Committee's certification of the European Medicines Agency approval of the Marketing Authorization Application for Pacritinib, assuming that such approval occurs no later than September 30, 2019.
David H. Kirske
2018-09-20